$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
爱博新(帕博西尼)是全球首个批准上市的CDK4/6激酶抑制剂
2025-10-19 11:44:20
Check Details
乳腺癌吃奥拉帕利多久才会有效果?
2025-10-19 11:44:20
Check Details
爱博新联合氟维司群可以有效提高患者生存期
2025-10-19 11:44:20
Check Details
爱博新联合氟维司群治疗晚期乳腺癌的效果
2025-10-19 11:44:20
Check Details
阿哌利西可以用于哪些肿瘤的治疗?
2025-10-19 11:44:20
Check Details
患者使用阿哌利西治疗前需要了解的事项
2025-10-19 11:44:20
Check Details
阿哌利西+氟维司群治疗乳腺癌可有效降低死亡风险
2025-10-19 11:44:20
Check Details
阿哌利西获批用于治疗PIK3CA突变的乳腺癌患者
2025-10-19 11:44:20
Check Details
阿哌利西+氟维司群治疗PIK3CA突变乳腺癌可显著延长无进展生存期
2025-10-19 11:44:20
Check Details
阿哌利西+氟维司群治疗PIK3CA突变患者的疗效与安全
2025-10-19 11:44:20
Check Details
乳腺癌患者服用泰立沙的禁忌和注意事项
2025-10-19 11:44:20
Check Details
乳腺癌患者服用阿哌利西多长时间才有效果?
2025-10-19 11:44:20
Check Details
1
2
...
2000
2001
2002
2003
2004
2005
2006
...
4157
4158
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
2
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
3
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
4
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
5
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
6
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
7
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
8
Chemical Structure of Capivasertib: A Novel AKT Inhibitor
9
Capivasertib: An AKT Inhibitor for Breast and Prostate Cancer
10
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
11
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
12
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations